Rhythm Pharmaceuticals Inc. (RYTM) Cash Flow Statement Analysis - Operating Cash Flow, CapEx & Free Cash Flow - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Rhythm Pharmaceuticals In...

    NASDAQ: RYTM · Real-Time Price · USD
    102.00
    1.73 (1.73%)
    At close: Sep 11, 2025, 10:06 AM

    Rhythm Pharmaceuticals Cash Flow Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Net Income
    		 -260.6M -184.68M -181.12M -69.61M
    Depreciation & Amortization
    		 1.56M 1.76M 1.67M 1.16M
    Stock-Based Compensation
    		 39.68M 32.55M 19.83M 20.8M
    Other Working Capital
    		 2.42M 4.38M -13.26M -15.15M
    Other Non-Cash Items
    		 94.9M 9.4M 5.91M -250K
    Deferred Income Tax
    		 n/a n/a n/a -100M
    Change in Working Capital
    		 10.57M 4.81M -19.72M 1.9M
    Operating Cash Flow
    		 -113.88M -136.16M -173.43M -146M
    Capital Expenditures
    		 n/a -47K -4.28M -5.43M
    Cash Acquisitions
    		 n/a n/a 4M 100M
    Purchase of Investments
    		 -268.31M -354.92M -251.94M -524.97M
    Sales Maturities Of Investments
    		 260.64M 354.97M 284.25M 361.25M
    Other Investing Acitivies
    		 -40.5M -5.67M -4M 7M
    Investing Cash Flow
    		 -48.17M -5.67M 28.03M -62.16M
    Debt Repayment
    		 n/a n/a n/a n/a
    Common Stock Repurchased
    		 n/a n/a n/a n/a
    Dividend Paid
    		 n/a n/a n/a n/a
    Other Financial Acitivies
    		 n/a 25.49M 82.72M 4.75M
    Financial Cash Flow
    		 191.24M 74.37M 213.83M 166.48M
    Net Cash Flow
    		 29.19M -67.6M 68.43M -41.68M
    Free Cash Flow
    		 -113.88M -136.2M -177.71M -151.44M

    Add to Watchlist